Imetelstat for Blood Cancers

No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Prior Safety DataThis treatment has passed at least one previous human trial

What You Need to Know Before You Apply

What is the purpose of this trial?

To learn if imetelstat can help to control MDS/MPNs.

Who Is on the Research Team?

BG

Bravo G Montalban, MD

Principal Investigator

M.D. Anderson Cancer Center

Are You a Good Fit for This Trial?

Inclusion Criteria

I meet the requirements to join this clinical trial.
I have used hydroxyurea or blood growth factors before starting this treatment.
I am able to care for myself and do light activities.
See 7 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive Imetelstat intravenously every 4 weeks

12 months

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

  • Imetelstat

How Is the Trial Designed?

1

Treatment groups

Experimental Treatment

Group I: SingleArm: Treatment with Imetelstat (IV) Q4WExperimental Treatment1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

M.D. Anderson Cancer Center

Lead Sponsor

Trials
3,107
Recruited
1,813,000+

Geron Corporation

Industry Sponsor

Trials
20
Recruited
1,500+